How to differentiate between clinical added value (CAV) V drugs: What are the implications, and what is the access pathway?

Clémentine Body, Frédéric Chassagnol, Driss Berdaï, Jean-François Bergmann, Isabelle Borget, Carole Doré, Alexandra Durr, Bruno Falissard, Joumana Hudry, Benjamin Kowalski, Philippe Maugendre, Nicolas Schlumberger, Elodie Wilmet, Claire Le Jeunne

Open source

DOI
10.1016/j.therap.2025.10.010
Published
2026-01
Container
Therapies
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.therap.2025.10.010,
  title = {How to differentiate between clinical added value (CAV) V drugs: What are the implications, and what is the access pathway?},
  author = {Clémentine Body and Frédéric Chassagnol and Driss Berdaï and Jean-François Bergmann and Isabelle Borget and Carole Doré and Alexandra Durr and Bruno Falissard and Joumana Hudry and Benjamin Kowalski and Philippe Maugendre and Nicolas Schlumberger and Elodie Wilmet and Claire Le Jeunne},
  year = {2026},
  journal = {Therapies},
  doi = {10.1016/j.therap.2025.10.010},
  url = {https://doi.org/10.1016/j.therap.2025.10.010}
}

RIS

TY  - JOUR
TI  - How to differentiate between clinical added value (CAV) V drugs: What are the implications, and what is the access pathway?
AU  - Clémentine Body
AU  - Frédéric Chassagnol
AU  - Driss Berdaï
AU  - Jean-François Bergmann
AU  - Isabelle Borget
AU  - Carole Doré
AU  - Alexandra Durr
AU  - Bruno Falissard
AU  - Joumana Hudry
AU  - Benjamin Kowalski
AU  - Philippe Maugendre
AU  - Nicolas Schlumberger
AU  - Elodie Wilmet
AU  - Claire Le Jeunne
PY  - 2026
JO  - Therapies
DO  - 10.1016/j.therap.2025.10.010
UR  - https://doi.org/10.1016/j.therap.2025.10.010
ER  - 

APA

Body, C., Chassagnol, F., Berdaï, D., Bergmann, J., Borget, I., Doré, C., Durr, A., Falissard, B., Hudry, J., Kowalski, B., Maugendre, P., Schlumberger, N., Wilmet, E., & Jeunne, C. L. (2026). How to differentiate between clinical added value (CAV) V drugs: What are the implications, and what is the access pathway?. Therapies. https://doi.org/10.1016/j.therap.2025.10.010

Source records